Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$30.11

-2.61 (-7.98%)

07:25
02/27/18
02/27
07:25
02/27/18
07:25

Aimmune price target raised to $62 from $55 at RBC Capital

RBC Capital analyst Kennen MacKay raised his price target on Aimmune to $62, citing the company's PALISADE data announcement that meets and exceeds his expectations for AR101 efficacy and safety. MacKay keeps his Outperform rating, saying the treatment is " well-positioned to disrupt and build the peanut allergy desensitization market" and awaits the full presentation of the phase 3 findings at next week's AAAAI conference.

  • 02

    Mar

  • 11

    Mar

AIMT Aimmune
$30.11

-2.61 (-7.98%)

02/20/18
ROTH
02/20/18
NO CHANGE
Target $75
ROTH
Buy
Aimmune data better than expected, says Roth Capital
Roth Capital analyst Jotin Marango says that Aimmune's topline PALISADE data carried several positive surprises and no negative surprises. Overall, the analyst notes that the efficacy looked strong and in line with his prior guidance, while components of the safety profile looked better than he expected based on historical OIT. Marango reiterates a Buy rating and $75 price target on the shares ahead of full data at AAAAI in Orlando on March 4.
02/20/18
FBCO
02/20/18
NO CHANGE
Target $45
FBCO
Outperform
Credit Suisse views Aimmune positively, surprised by stock reaction
Credit Suisse analyst Vamil Divan notes that Aimmune announced that its pivotal Phase 3 trial for peanut allergy treatment AR101, PALISADE, met its primary and secondary efficacy endpoints. The analyst is not surprised by the data, but by the selloff with the stock, which he believes may be related to profit-taking given the large stock movement over the 12-18 months and the lack of meaningful catalysts over the next several months until potential approval of AR101 in 2H19. Divan maintains his 80% probability of success of AR101, and reiterates an Outperform rating and $45 price target on the shares.
02/20/18
DBAB
02/20/18
NO CHANGE
Target $30
DBAB
Buy
Deutsche sees room for multiple players in peanut allergy space
Aimmune Therapeutics' (AIMT) top-line results from the Palisade study suggest that AR101 could be an effective treatment for the desensitization of peanut allergy patients to peanut protein, Deutsche Bank analyst Andrew Peters tells investors in a research note. The analyst, however, believes AR101 "continues to be a potentially challenging therapy from a tolerability and safety perspective" with 20.4% of patients discontinuing therapy for all causes. AR101's profile is "far from suggestive of an all-encompassing option for patients," leaving "meaningful opportunity" for other agents, Peters contends. As such, he sees room for both AR101 and DBV Technologies' (DBVT) Viaskin Peanut. The analyst keeps a Buy rating on DBV shares with a $30 price target.
02/27/18
PIPR
02/27/18
NO CHANGE
Target $62
PIPR
Overweight
Aimmune target raised to $62 following capital raise at Piper Jaffray
Aimmune Therapeutics' recent capital raise extends its runway to mid-2020 and reduces overall clinical and commercial risk for AR101, Piper Jaffray analyst Charles Duncan tells investors in a research note. The analyst continues to see the recent Palisade data as compelling, and even exceeding his expectations, on efficacy and tolerability. To reflect a more favorable commercial outlook, Duncan raised his price target for Aimmune shares to $62 from $60. He reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

05:23
07/23/18
07/23
05:23
07/23/18
05:23
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

05:22
07/23/18
07/23
05:22
07/23/18
05:22
Hot Stocks
Roche receives CE Mark for Accu-Chek Solo micropump system »

Roche announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

PZZA

Papa John's

$51.61

0.62 (1.22%)

05:22
07/23/18
07/23
05:22
07/23/18
05:22
Hot Stocks
Papa John's adopts limited duration stockholder rights plan »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

05:21
07/23/18
07/23
05:21
07/23/18
05:21
General news
Trump tells Iranian President to 'never, ever threaten' U.S. again »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STIM

Neuronetics

$26.27

-0.44 (-1.65%)

05:19
07/23/18
07/23
05:19
07/23/18
05:19
Initiation
Neuronetics initiated  »

Neuronetics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$51.61

0.62 (1.22%)

05:17
07/23/18
07/23
05:17
07/23/18
05:17
Downgrade
Papa John's rating change  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$166.47

-0.47 (-0.28%)

05:16
07/23/18
07/23
05:16
07/23/18
05:16
Hot Stocks
Accenture forms strategic alliance with Ripjar, terms not disclosed »

Accenture has formed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

BV

BrightView

$21.95

0.14 (0.64%)

05:12
07/23/18
07/23
05:12
07/23/18
05:12
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCDA

Tricida

$29.50

-0.42 (-1.40%)

05:10
07/23/18
07/23
05:10
07/23/18
05:10
Initiation
Tricida initiated  »

Tricida initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

BrightView

$21.95

0.14 (0.64%)

05:08
07/23/18
07/23
05:08
07/23/18
05:08
Initiation
BrightView initiated  »

BrightView initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSM

Insmed

$24.98

-0.12 (-0.48%)

05:07
07/23/18
07/23
05:07
07/23/18
05:07
Initiation
Insmed initiated  »

Insmed initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 28

    Sep

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

05:04
07/23/18
07/23
05:04
07/23/18
05:04
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BJ

BJ's Wholesale

$25.90

0.23 (0.90%)

05:01
07/23/18
07/23
05:01
07/23/18
05:01
Initiation
BJ's Wholesale initiated  »

BJ's Wholesale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DUK

Duke Energy

$80.64

-0.56 (-0.69%)

04:58
07/23/18
07/23
04:58
07/23/18
04:58
Upgrade
Duke Energy rating change  »

Duke Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

STI

SunTrust

$70.86

1.855 (2.69%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Upgrade
SunTrust rating change  »

SunTrust upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
RBC Capital commodity strategist to hold a dinner meeting »

Commodity Strategist…

MGEN

Miragen Therapeutics

$6.87

-0.08 (-1.15%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
Miragen Therapeutics management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

SAR

Saratoga Investment

$24.59

0.08 (0.33%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
Saratoga Investment management to meet with Compass Point »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

NTEC

Intec Pharma

$4.75

(0.00%)

04:55
07/23/18
07/23
04:55
07/23/18
04:55
Conference/Events
Intec Pharma management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

June Chicago Fed National…

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
07/23/18
07/23
04:55
07/23/18
04:55
General news
Existing Home Sales to be reported at 10:00 »

June Existing Home Sales…

CCLAY

Coca-Cola Amatil

$0.00

(0.00%)

04:52
07/23/18
07/23
04:52
07/23/18
04:52
Downgrade
Coca-Cola Amatil rating change  »

Coca-Cola Amatil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.